There is no specific treatment in the event of overdose of Gefitinib. Adverse reactions associated with overdose should be treated symptomatically; in particular severe diarrhea should be managed as clinically indicated. In phase I clinical trials, a limited number of patients were treated with daily doses of up to 1000 mg. An increase of frequency and severity of some adverse reactions was observed, mainly diarrhea and skin rash. In one study a limited number of patients were treated weekly with doses from 1500 mg to 3500 mg. In this study Gefitinib exposure did not increase with increasing dose, adverse events were mostly mild to moderate in severity, and were consistent with the known safety profile of Gefitinib.
Sign Out
